Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Norway

Research and Innovation Action · Running

EBV-MS Targeting Epstein-Barr Virus Infection for Treatment and Prevention of Multiple Sclerosis

Coordinator
Universitetet I Bergen, Norway
Runs
1 December 2023 to 30 November 2028
Status
Running
EU funding
€7.5m
Total cost
€8.2m
Partners
16 organisations in 7 countries
Type
Research and Innovation Action
Grant agreement
101136991

What the project is doing

In the project's own words, from its summary on CORDIS.

Multiple sclerosis (MS) is a chronic inflammatory and degenerative disease of the central nervous system (CNS). It constitutes the most common non-traumatic cause of neurological impairment among young and middle-aged people and represents a major healthcare burden. Our recent research strongly implicates infection by the Epstein-Barr virus (EBV) as the leading cause of MS, but detailed understanding of the mechanisms how EBV contributes to the disease, and whether targeting EBV could prevent or improve the course remain unresolved.

To meet these challenges, we have established a consortium with extensive experience in neurology and MS, genetics, virology and EBV, epidemiology, immunology, clinical trials, artificial intelligence, as well as stakeholder involvement and responsible research and innovation (RRI). By combining this expertise, the consortium takes advantage of high-quality health registries, existing research cohorts of persons with MS, and prospective randomized clinical trials of antiviral therapies targeting the EBV infection in MS.

The ambitious goals are to answer the questions why only a few EBV infected persons develop MS, and define the underlying mechanism of this process, as well as clarify if targeting the EBV infection can prevent MS or improve the disease course. By answering these questions, we would meet the challenges defined in the current call: Relationship between infections and non-communicable diseases. We would contribute with knowledge to reduce disease burden by providing the health care system with new knowledge to better understand the cause of MS, including host risk factors that influence the development of the disease.

We would also provide a basis for new or improved tools to prevent MS or disease progression. Healthcare practitioners will gain access to knowledge to guide them on preventive measures and of those persons at risk of developing MS, with the ultimate goal of eradicating the disease.

Topics

Who is involved

OrganisationCityCountryRole
Universitetet I BergenBergenNorwayCoordinator
The European Multiple Sclerosis Platform AisblBruxelles / BrusselBelgiumParticipant
Kypriako Idryma Erevnon Gia Ti Myiki DistrofiaAgios DometiosCyprusParticipant
Fundacio Centre De Regulacio GenomicaBarcelonaSpainParticipant
Fundacio Institut Hospital Del Mar D Investigacions MediquesBarcelonaSpainParticipant
Universidad Pompeu FabraBarcelonaSpainParticipant
Fondazione Italiana Sclerosi Multipla - Fism EtsGenovaItalyParticipant
Irccs San Raffaele Roma SRLRoma RmItalyThird party
Universita Degli Studi Di Roma La SapienzaRomaItalyParticipant
Akershus Universitetssykehus HfLorenskogNorwayThird party
Helse Bergen HfBergenNorwayParticipant
Helse Stavanger HfStavangerNorwayThird party
Oslo Universitetssykehus HfOsloNorwayParticipant
Vestre Viken HtDrammenNorwayThird party
Karolinska InstitutetStockholmSwedenParticipant
Harvard Global Research and Support Services Inc.CambridgeUnited StatesParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI